药品详细

Mefenamic acid (甲芬那酸 )

基本信息
剂型规格
适应症
药理
临床
理化性质
相互作用
文档
专利
Pathway
文献
序列

化学结构式图

中文名

甲芬那酸

英文名

Mefenamic acid

分子式

Not Available

化学名

2-[(2,3-dimethylphenyl)amino]benzoic acid

分子量

Average: 241.2851
Monoisotopic: 241.110278729

CAS号

61-68-7

ATC分类

M01A 未知

药物类型

small molecule

阶段

商品名

Bafameritin-M;Bafhameritin-M;Bonabol;Coslan;HL 1;In-M;Lysalgo;Mefacit;Namphen;Parkemed;Ponalar;Ponstan;Ponstan Forte;Ponstel;Ponstil;Ponstyl;Pontal;Tamany Bonsan;Tanston;Vialidon;

同义名

Acide Mefenamique;Mefanamic Acid;Mefenacid;Mefenaminsaeure;Mephenamic Acid;Mephenaminic Acid;Methenamic Acid;

基本介绍

A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase. [PubChem]

生产厂家

Shionogi pharma inc

封装厂家

参考

Synthesis Reference	Not Available
General Reference	Not Available

剂型

Form	Route	Strength
Capsule	Oral

规格

Unit description	Cost	Unit
Ponstel 250 mg capsule	11.85 USD	capsule
Mefenamic acid powder	2.85 USD	g
Ponstel 250 mg kapseals	1.59 USD	each
Apo-Mefenamic 250 mg Capsule	0.52 USD	capsule

化合物类型

Type	small molecule

Classes

Aminobenzoates

Substructures

Aminobenzoates
Hydroxy Compounds
Benzyl Alcohols and Derivatives
Acetates
Benzoates
Aliphatic and Aryl Amines
Benzene and Derivatives
Carboxylic Acids and Derivatives
Aromatic compounds
Benzoyl Derivatives
Anilines

适应症

ANTIINFLAMMATORY AND ANTIRHEUMATIC 消炎抗风湿;

药理

Indication

For the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever.

Pharmacodynamics

Mefenamic acid, an anthranilic acid derivative, is a member of the fenamate group of nonsteroidal anti-inflammatory drugs (NSAIDs). It exhibits anti-inflammatory, analgesic, and antipyretic activities. Similar to other NSAIDs, mefenamic acid inhibits prostaglandin synthetase.

Mechanism of action

Mefenamic acid binds the prostaglandin synthetase receptors COX-1 and COX-2, inhibiting the action of prostaglandin synthetase. As these receptors have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity, the symptoms of pain are temporarily reduced.

Absorption

Mefenamic acid is rapidly absorbed after oral administration.

Volume of distribution

1.06 L/kg [Normal Healthy Adults (18-45 yr)]

Protein binding

90%

Metabolism

Mefenamic acid undergoes metabolism by CYP2C9 to 3-hydroxymethyl mefenamic acid, and further oxidation to a 3-carboxymefenamic acid may occur. The activity of these metabolites has not been studied. Mefenamic acid is also glucuronidated directly.

Route of elimination

The fecal route of elimination accounts for up to 20% of the dose, mainly in the form of unconjugated 3-carboxymefenamic acid.3 The elimination half-life of mefenamic acid is approximately two hours. Mefenamic acid, its metabolites and conjugates are primarily excreted by the kidneys. Both renal and hepatic excretion are significant pathways of elimination.

Half life

2 hours

Clearance

Oral cl=21.23 L/hr [Healthy adults (18-45 yrs)]

Toxicity

Oral, rat LD₅₀: 740 mg/kg. Symptoms of overdose may include severe stomach pain, coffee ground-like vomit, dark stool, ringing in the ears, change in amount of urine, unusually fast or slow heartbeat, muscle weakness, slow or shallow breathing, confusion, severe headache or loss of consciousness.

Affected organisms

Humans and other mammals

Pathways

Pathway	Name	SMPDB ID
	Mefanamic Acid Pathway	SMP00109

理化性质

Properties

State

solid

Melting point

230-231 oC

Experimental Properties

Property	Value	Source
water solubility	20 mg/L	PhysProp
logP	4.2	PhysProp
logS	-3.78 [ADME Research, USCD]	PhysProp
pKa	4.2	Various sources

Predicted Properties

Property	Value	Source
water solubility	1.37e-02 g/l	ALOGPS
logP	4.58	ALOGPS
logP	5.40	ChemAxon Molconvert
logS	-4.25	ALOGPS
pKa	17.77	ChemAxon Molconvert
hydrogen acceptor count	3	ChemAxon Molconvert
hydrogen donor count	2	ChemAxon Molconvert
polar surface area	49.33	ChemAxon Molconvert
rotatable bond count	3	ChemAxon Molconvert
refractivity	71.88	ChemAxon Molconvert
polarizability	26.22	ChemAxon Molconvert

药物相互作用

Drug	Interaction
Acenocoumarol	The NSAID, mefanamic acid, may increase the anticoagulant effect of acenocoumarol.
Alendronate	Increased risk of gastric toxicity
Anisindione	The NSAID, mefanamic acid, may increase the anticoagulant effect of anisindione.
Cyclosporine	Monitor for nephrotoxicity
Dicumarol	The NSAID, mefanamic acid, may increase the anticoagulant effect of dicumarol.
Lithium	The NSAID, mefenamic acid, may decrease the renal excretion of lithium. Increased risk of lithium toxicity.
Methotrexate	The NSAID, mefenamic acid, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity.
Tamoxifen	Mefenamic acid may reduce clearance rate of Tamoxifen. Monitor for changes in therapeutic/adverse effects of Tamoxifen if Mefenamic acid is initiated, discontinued or dose changed.
Tolbutamide	Mefanamic acid, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Tolbutamide, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in Tolbutamide therapeutic and adverse effects if Mefanamic acid is initiated, discontinued or dose changed.
Torasemide	Mefanamic acid, a strong CYP2C9 inhibitor, may increase the serum concentration of Torasemide, a CYP2C9 substrate, by decreasing Torasemide metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Torasemide if Mefanamic acid is initiated, discontinued or dose changed.
Trandolapril	The NSAID, Mefenamic acid, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Mefenamic acid is initiated, discontinued or dose changed.
Treprostinil	The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Mefenamic acid. Monitor for increased bleeding during concomitant thearpy.
Trimethoprim	The strong CYP2C9 inhibitor, Mefenamic acid, may decrease the metabolism and clearance of Trimethoprim, a CYP2C9 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimethoprim if Mefenamic acid is initiated, discontinued or dose changed.
Voriconazole	Mefanamic acid, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if mefanamic acid is initiated, discontinued or dose changed.
Warfarin	Mefenamic acid, a strong CYP2C9 inhibitor, may decrease the metabolism of warfarin. The antiplatelet effect of mefenamic acid may also increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if mefenamic acid is initiated, discontinued or dose changed.

食物相互作用

Avoid alcohol.
Take with food.

返回 | 收藏